Clinical trial
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With…
NCT00082407 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00082407 |
|---|---|
| Title | Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin |
| Official title | Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | exenatide, biphasic insulin aspart |
| Enrollment | 505 |
| Start date | Nov 1, 2003 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | May 10, 2004 |
| Last update posted | Apr 7, 2015 |
| Countries | Croatia, Germany, Greece, Italy, Netherlands, Portugal, Romania, Russia, Slovenia, Spain, Taiwan, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: